This week's roundup of Houston innovators includes Steve Latham of DonateStock, Arianne Dowdell of Houston Methodist, and Howard Berman of Coya Therapeutics. Photos courtesy

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from fintech to health care DEI — recently making headlines in Houston innovation.

Steve Latham, co-founder and CEO of DonateStock

Houstonian and serial entrepreneur plans to scale nonprofit fintech toolThe sky's the limit for DonateStock, Co-Founder and CEO Steve Latham says. Photo courtesy of DonateStock

For the third time in his career, serial entrepreneur Steve Latham recession activity, so he feels confident he knows the playbook of how to handle what's on the horizon. For his latest venture, Donate Stock, a tech platform that simplifies stock donation for both the donor and the beneficiary, he's focused on weathering whatever storm is incoming.

"We've raised more money to extend our runway, and we're keeping a super tight lid on expenses because your cash is your oxygen," he says. "There are companies going out of business in our industry right now that had really promising businesses but just spent too much money before they could get to the revenue phase."

He shares the background story on DonateStock and his own career on last week's Houston Innovators Podcast episode. Read more and stream the episode.

Arianne Dowdell, vice president and chief diversity, equity and inclusion officer at Houston Methodist

Arianne Dowdell spoke with InnovationMap about Houston Methodist's DEI initiatives — and how they will help develop the hospital of the future. Photo courtesy of Houston Methodist

Innovation and equity are two things they have to go together — and Houston Methodist knows that. Which is why Arianne Dowdell serves as vice president and chief diversity, equity and inclusion officer at Houston Methodist. Under her leadership, the health care provider is putting the patients at the forefront of the hospital system's priorities through its DEI initiatives.

In an interview with InnovationMap, Dowdell shares more about these ongoing initiatives and her role, as well as the importance of DEI in innovative health care.

"It doesn't matter if you're down here in the medical center or out in Baytown," she says. "The innovation and what we're thinking about and the technologies and the way that we communicate with our patients, all that is part of innovation, which helps our DEI initiatives become more successful in everything that we're doing." Read more.

Howard Berman, CEO of Coya Therapeutics

A Houston biotech startup focused on developing therapeutics for neurodegenerative and autoimmune diseases has closed its IPO. Photo courtesy of Coya

A clinical-stage biotech company based in Houston has announced the closing of its $15.25 million IPO.

Coya Therapeutics, now trading under the ticker COYA, announced this week that its IPO — previously disclosed in December — has closed its initial public offering of 3,050,000 shares of its common stock and accompanying warrants to purchase up to 1,525,000 shares of common stock, per a news release. Howard Berman, CEO of Coya Therapeutics, has lead the company since February of 2021. Read more.

The sky's the limit for DonateStock, Co-Founder and CEO Steve Latham says. Photo courtesy of DonateStock

Houstonian and serial entrepreneur plans to scale nonprofit fintech tool

Houston innovators podcast episode 167

Donating stock can be a smart way to offload assets and optimize a donation — but Steve Latham thought it was so cumbersome a process that it didn't even feel worth it.

"It was such a hassle that I never did it again," says Latham on the Houston Innovators Podcast.

That opportunity for innovation stuck with Latham as he advanced his career in AdTech in New York before moving back to Houston a few years ago. A serial entrepreneur, Latham was an early co-founder of the Houston Technology Center.

His latest venture is DonateStock — a tech platform that simplifies stock donation for both the donor and the beneficiary. The early version of Latham's vision was to clear up the lack of communication the original process had — nonprofits receiving stock donations were never notified about who made each donation.

The next phase for the fintech company, as Latham explains on the show, is to scale this idea by way of channel distribution, rather than just directly working between donor and nonprofit. He says he wants DonateStock to be a featured as an "easy button" option wherever donations are accepted online.

"Now that we've proven and shown that our process works," he says, "let's scale that to make that button available to the 20 or so online donation platforms."

In order to accomplish this goal, Latham is preparing to fundraise early this year, but it's a challenging time for fintech amid economic uncertainty, he says. So far, the company has raise $2.25 million from within the company's network along with angel and family office investment.

"We've raised more money to extend our runway, and we're keeping a super tight lid on expenses because your cash is your oxygen," he says. "There are companies going out of business in our industry right now that had really promising businesses but just spent too much money before they could get to the revenue phase."

This is the third time in Latham's career that he's seen this recession activity, so he feels confident he knows the playbook of how to handle what's on the horizon.

Latham shares more about the difference his company is making within the nonprofit sector, as well as his passion for Houston and its local tech ecosystem — which he's seen grow up from afar — on the podcast episode. Stream the episode below, or wherever you listen to your podcasts.


DonateStock, a Houston fintech company that simplifies the stock donation process, has officially launched. Image courtesy of DonateStock

Impact-driven Houston fintech startup officially launches after successful beta

it's go time

Keep reading...Show less
Houston-based DonateStock is $50,000 richer after claiming a recent pitch competition win. Photo via donatestock.com

Houston fintech startup snags Capital Factory's $50,000 pitch investment prize

winner, winner

Capital Factory, one of the most active startup investors with a presence across Texas, recently hosted a virtual pitch competition — and one Houston startup took home the big prize.

As a part of the Houston Tech Rodeo, Capital Factory hosted its $50K Houston Investment Challenge with five finalists — DonateStock, Elastique, Elemental Coatings, M&S Biotics, and ScalaMed. The panel of judges included Andy Cloyd, vice president of Revolution; Aleece Hobson, venture partner at HX Venture Fund; and Juliana Garaizar launch director of Greentown Labs.

DonateStock, a tech-enabled tool that automates the stock donation process, took home the big win. Steve Latham, founder and chairman of DonateStock, presented the company's pitch and explained how the tool has the potential to unlock $100 billion for nonprofits.

"A lot of people aren't aware about the benefits of donating stock," Latham explains. "If you're sitting on stock that you've owned or several years that's appreciated quite a bit. If you sell it, you pay capital gains tax — anywhere from 15 to 30 percent. If you donate it, you avoid the tax and you get a big write off, you can deduct the full market value of the donated stock."

He goes on to explain how only 2 percent of people donate stock — and its due to the archaic process that it takes. DonateStock's platform optimizes the education of donors, the connection of nonprofits to new donors, and the simplification of the process. What used to take hours now takes just 10 minutes, Latham says.

Nonprofits get a free page, free customer support, and there is no fee to be on the platform, and DonateStock makes a 2 percent transaction fee. The company already has 40 nonprofits on the platform, and over 70 in the queue to sign up. The goal, Latham says, is to have 900 organizations online by the end of the year. He's already seen a lot of interest in light of the pandemic.

"This is the time to solve this problem," Latham says. "If you have friends at nonprofits or charities, you know what the pandemic did to giving programs. They've all been devastated and they have gotta find new ways to diversify and grow their revenue."

DonateStock anticipates a seed round later this year. It's the third startup Latham has worked on with his co-founder.

"We see a path to building a billion-dollar company over the next five years while impacting millions of lives around the world," he says.

Each of the other finalists' consolation prize is a connection and a foot in the door at Capital Factory, says CEO Joshua Baer.

"Every time we do one of these, we meet a bunch of companies that we end up working with — and many of whom we end up investing in," he says at the virtual event. "We're going to be following up with all of the companies from today. Anyone who was a finalist and up on the stage is someone we are excited about and interested in working more closely with."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.

Elon Musk's SpaceX is about to make its debut on Wall Street

Money Moves

Elon Musk's rocket company SpaceX will make its debut on Wall Street Friday, June 12, and both institutional and retail investors are expected to gobble up the 555.6 million shares going up for sale at $135 apiece. Musk, already the world's richest man, could become its first trillionaire.

SpaceX is likely to become the biggest IPO ever, with proceeds of around $75 billion. SpaceX hopes to become the first company to send people to Mars. In fact, part of Musk’s future compensation depends on SpaceX eventually establishing a colony of at least 1 million people on the red planet.

Why SpaceX is going public now

In a video conference on Musk's social media platform X, he told JPMorgan CEO Jamie Dimon that people have suggested for the last 10 years that he take SpaceX public. He's doing it now because the company plans to put 100,000 next-generation Starlink satellites into orbit. Deploying AI data centers in space is a “massive new growth base and you need capital for that,” he said.

Going public provides access to the capital that SpaceX needs. But it also exposes it to more scrutiny from shareholders and more regulatory oversight. That includes filing quarterly financial reports, which critics say incentivizes short-term thinking over longer-term planning and creates unnecessary costs for a company. Securities regulators are currently soliciting public comment on a proposal to require public companies to file the financial reports only twice every year.

How the IPO impacts the company

Musk will hold the majority of a special class of shares, giving him control over decisions related to company strategy, finances and personnel. On the latter, because of his ownership of most of these Class B shares, the only person who can fire Musk as CEO is Musk.

The company credits Musk with being the “driving force” behind its growth, innovation and success. But what happens if Musk is no longer in the picture? SpaceX warns that the loss of Musk could disrupt its ability to execute its strategy as well as hurt its “reputation and relationships with customers, partners and other stakeholders.”

The company also warns that finding a replacement with the same skills and experience as Musk would be time-consuming, if not nearly impossible. As Wedbush Securities analyst Dan Ives wrote Wednesday, “At the end of the day Musk is SpaceX and SpaceX is Musk.”

What could make or break SpaceX

Currently in the test phase, the gigantic reusable Starship rocket is key to SpaceX realizing Musk's ambitions. Much of the commercial space business hinges on SpaceX developing Starship’s capability to be fully reusable and hearty enough for a quick turnaround between flights. If that doesn't happen, SpaceX warns that putting data centers and satellites in space will take longer and cost more money, meaning it risks customers bailing on the company.

Analysts say that by pioneering reusable rockets, SpaceX has established a clear lead on competitors such as Blue Origin, led by Amazon founder Jeff Bezos. The Starlink satellite business competes with, among others, AST SpaceMobile – which is relying on a SpaceX rocket to send its latest generation of satellites into orbit next week.

The prospectus filed last week says SpaceX’s biggest potential market is the sale of business-oriented artificial intelligence products designed to transform how people get work done. It’s an opportunity SpaceX predicts would be worth $22.7 trillion if it could somehow dominate rivals like Anthropic, OpenAI and Microsoft in a highly competitive industry. But the prospectus shows no clear path to profitability for the xAI business, which merged with SpaceX earlier this year.

Why Wall Street is paying attention

If the SpaceX IPO is as successful, the stock could quickly join the Nasdaq 100, a widely followed index that tracks the 100 largest non-financial companies in the composite. That's important because some popular funds, such as the $460 billion QQQ exchange-traded fund, mimic the index and will automatically buy whatever is listed in the index.

Nasdaq recently changed its rules to allow select companies to enter the Nasdaq 100 after just 15 trading days.

S&P Dow Jones Indices, on the other hand, is sticking to established and more traditional thresholds that will not allow SpaceX or other companies with gargantuan IPOs faster entry into its S&P 500 index. That means even high-profile companies will still need to wait for their stocks to trade a full 12 months before they can enter the index.

Companies want to be in the S&P 500 in particular because it's arguably the most important index on Wall Street, with trillions of dollars either mimicking it exactly or benchmarked against it. Vanguard's VOO fund that tracks the S&P 500 has roughly $950 billion invested in it, for example.